Navigation Links
INNOPHARMA Receives FDA Approval of Generic Olanzapine Injection
Date:10/25/2011

PISCATAWAY, N.J., Oct. 25, 2011 /PRNewswire/ -- INNOPHARMA LLC announced today FDA approval of its Abbreviated New Drug Application (ANDA) for olanzapine injection (the generic equivalent of Zyprexa® injection).

As the developer of this generic injectable drug, INNOPHARMA entered into an agreement with Sandoz Inc., pursuant to which Sandoz will sell, market and distribute the product in the United States.  

About INNOPHARMA:

INNOPHARMA is a sterile product development company, focused on developing niche generic and specialty pharmaceutical products.  Through a business model of internal product development and commercialization licensure, INNOPHARMA has a comprehensive infrastructure for development of injectable and ophthalmic pharmaceutical products at its New Jersey facilities.  INNOPHARMA works with manufacturing and clinical research organizations worldwide for commercialization of its developed products.  More information about INNOPHARMA can be found at www.innopharmallc.com.    

Zyprexa® is a registered trademark of Eli Lilly and Company


'/>"/>
SOURCE INNOPHARMA LLC
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. INNOPHARMA Receives FDA Approval of Generic Levetiracetam Injection
2. INNOPHARMA Receives First FDA Approval
3. Accuray Receives 510(k) Clearance for a Rotational Dose Control for the TomoTherapy System
4. Neuralstem Receives FDA Approval to Dose Patients in Cervical Region in Ongoing ALS Trial
5. Covance Receives Good Laboratory Practice Certification for Its Early Development Facility in Shanghai, China
6. Boca Pharmacal Receives FDA Approval on Glycopyrrolate Tablets
7. Institute of Health Sciences Receives ABHES Institutional Accreditation for Long Distance Education
8. Nutra Pharma Receives Patent for Their Multiple Sclerosis Drug
9. Luminex Corporation Receives Deloitte Technology Fast 500™ Award
10. NASCSA Receives $200,000 Grant from Purdue Pharma L.P. to Support State Prescription Drug Monitoring Programs
11. HipSextant™ Navigation System Receives Its First Commercial Use
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... DUBLIN, Ohio , July 24, 2014  As part ... owners, Cardinal Health will host its annual Pharmacy Ownership Boot ... Retail Business Conference in Washington, D.C. ... pharmacists the business knowledge and confidence needed to own their ... program has become the industry,s leading event for women pharmacists ...
(Date:7/24/2014)...  Xencor, Inc. (NASDAQ: XNCR ), a ... treatment of autoimmune diseases, asthma and allergic diseases, and ... results after market close on Thursday, July 31, 2014. ... the same day at 4:30 p.m. EDT (1:30 p.m. ... corporate update. The live call may be ...
(Date:7/24/2014)... MedVantx, Inc., the company that has ... in physician offices, MedStart Connect, today announced it ... medication non-adherence and hospital readmission rates specified in ... the Annals of Internal Medicine ... changes in generic medication pill color and shape ...
Breaking Medicine Technology:'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 2'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 3'Women in Pharmacy' Program Seeks to Expand Pharmacy Ownership 4Xencor to Host Second Quarter 2014 Financial Results Webcast and Conference Call 2Medication Non-Adherence Issue Highlighted in Annals of Internal Medicine Study Could Be Eliminated by a New Direct-to-Consumer Delivery Channel Ensuring Consistent Medication Appearance 2Medication Non-Adherence Issue Highlighted in Annals of Internal Medicine Study Could Be Eliminated by a New Direct-to-Consumer Delivery Channel Ensuring Consistent Medication Appearance 3
... Mass., Aug. 31, 2011 Syndax Pharmaceuticals, Inc ... management will present at the following upcoming fall financial ... New York, NY, September 8 at 8:30 AM ET ... Zurich, Switzerland, September 13, 11:15 AM CEST oncology panel ...
... Fla., Aug. 31, 2011 A recent study featured ... dispels the myth that physicians, offices use prostate cancer ... The article, "Utilization Trends in Prostate Cancer ... of both surgical and radiation therapy for management of ...
Cached Medicine Technology:Syndax Pharmaceuticals to Present at Upcoming Fall Financial Conferences 2Study Explores Utilization Trends for Prostate Cancer Treatments 2
(Date:7/24/2014)... (PRWEB) July 24, 2014 "My child ... know until morning," said an inventor from Cynthiana, Ky. ... can cause seizures, brain damage, hearing loss, vision problems ... would have alerted me to the fever immediately." , ... to continuously monitors the child’s temperature. The unit alerts ...
(Date:7/24/2014)... drinking is associated with upsurges in hospital admissions among ... Ontario, Canada is published online today in the scientific ... of Northern British Columbia Associate Professor of Psychiatry Dr. ... Ontario over a five-year period (2002-07) involving people aged ... the week in which Ontarians turned 19 the ...
(Date:7/24/2014)... are often slow and time-consuming. Therefore, development of ... is very important for improving food safety. , ... Institute, has studied new methods of characterising Salmonella ... in water, feed and food samples. , The ... which factors in pork meat processing may contribute ...
(Date:7/24/2014)... Brightree® , the leading provider ... solutions for the post-acute care industry, announced today ... the nation’s largest family-owned providers of prosthetics, orthotics, ... as its billing and business management platform ... – including business management and document management ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 July ... $138,000 in sealant and anesthesia reversal products to ... to help save young smiles. The donation of ... and Oraverse® was distributed to America’s ToothFairy Affiliate ... with vital oral health services. The America’s ToothFairy ...
Breaking Medicine News(10 mins):Health News:Wright & Filippis Implements Brightree’s Billing and Business Management Platform 2Health News:Wright & Filippis Implements Brightree’s Billing and Business Management Platform 3Health News:Wright & Filippis Implements Brightree’s Billing and Business Management Platform 4Health News:Septodont Donation Helps Children in Need 2
... Investigators at Hospital for Special Surgery, collaborating with researchers ... a gene called interferon regulator factor-8 (IRF-8) is involved ... disease), rheumatoid arthritis and osteoporosis. The study, which will ... the journal Nature Medicine , could lead to ...
... , , , ... Boehringer Ingelheim today announced that results from the RE-LY(R) (Randomized Evaluation ... largest atrial fibrillation (AF) outcomes trial ever conducted(1) (18,113 patients in ... the European Society of Cardiology Congress and published online in the ...
... , , WILMINGTON, Del., Aug. 30 ... the phase III head to head trial, PLATO (A Study of ... that ticagrelor (BRILINTA(TM)) has achieved greater efficacy in the primary endpoint, ... (9.8% vs. 11.7% at 12 months; 16% RRR; 95% CI, 0.77 ...
... watched by typical U.S. teens, analysis finds , FRIDAY, ... attract a significant proportion of teenage viewers are also ... research has found. , Using Nielsen Media Research advertising ... aired on cable TV from 2001 through 2006. The ...
... ... upheld to more stringent standards, including medical credentialing , with the influx of ... ... 29, 2009 -- According to an article from the Journal of General Internal Medicine, ...
... , ... national leader in deliciously healthy, ready to heat and eat meals, are applauding the ... weight loss is all about portion-controlled, properly balanced meals. , ... Lorton, VA (PRWEB) August 29, 2009 -- Officials at Diet-to-Go, ...
Cached Medicine News:Health News:Researchers identify protein involved in causing gum disease, osteoporosis, arthritis 2Health News:Researchers identify protein involved in causing gum disease, osteoporosis, arthritis 3Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 2Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 3Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 4Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 5Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 6Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 7Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 8Health News:Video: RE-LY Trial Met Primary Outcome for Reducing Incidence of Stroke or Systemic Embolism in Non-valvular Atrial Fibrillation Patients 9Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 2Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 3Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 4Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 5Health News:Video: Phase III Head to Head Trial Showed Ticagrelor Reduced Cardiovascular Death and Heart Attacks Over Clopidogrel in Acute Coronary Syndromes Patients 6Health News:Alcohol Ads on Cable TV Reach Young Audiences 2Health News:Alcohol Ads on Cable TV Reach Young Audiences 3Health News:Foreign Physician Growth in the U.S. and the Impact on Medical Credentialing 2Health News:Foreign Physician Growth in the U.S. and the Impact on Medical Credentialing 3Health News:Diet-to-Go Asks: Isn't it TIME You Listened to the Facts About Weight Loss? 2Health News:Diet-to-Go Asks: Isn't it TIME You Listened to the Facts About Weight Loss? 3
Full Handle Laseredge Implant Blade Knife, 5.2 mm angled bevel up. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Implant Blade Knife, 4.0 mm angled bevel up. Blade dimension: 15.2 mm x 4.0 mm x 3.0 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, straight. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Medicine Products: